Keros Therapeutics, Inc. (NASDAQ:KROS) institutional owners may be pleased with recent gains after 2.4% loss over the past year [Yahoo! Finance]
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: Yahoo! Finance
A total of 8 investors have a majority stake in the company with 50% ownership Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business To get a sense of who is truly in control of Keros Therapeutics, Inc. ( NASDAQ:KROS ), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 73% ownership. Put another way, the group faces the maximum upside potential (or downside risk). After a year of 2.4% losses, last week's 6.8% gain would be welcomed by institutional investors as a possible sign that returns might start trending higher. In the chart below, we zoom in on the different ownership groups of Keros Therapeutics. See our latest analysis for Keros Therapeutics What Does The Institutional Ownership Tell Us About Keros Therapeutics? Institutions typically measure themselves against a benchmark when reporting to their own investors, so the
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%? [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $105.00 price target on the stock.MarketBeat
- Morphic appoints Simon Cooper as CMO [Seeking Alpha]Seeking Alpha
- Morphic Appoints Dr. Simon Cooper as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $100.00 price target on the stock.MarketBeat
KROS
Earnings
- 2/28/24 - Beat
KROS
Sec Filings
- 4/17/24 - Form ARS
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- KROS's page on the SEC website